Psilocybin

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. During the second quarter, the Phase 2 CALMA trial of IGC-AD1 reached the Company's previously disclosed 146-patient baseline randomization target. Subsequent to quarter-end, CALMA has continued its final planned over-enrollment phase and is now within six additional randomizations of expected enrollment closure. Patient follow-up, database lock, unblinding, and topline analysis are expected to follow, with topline data anticipated in the fourth quarter of 2026. "CALMA is now approaching enrollment closure, and our focus is on execution, patient follow-up, data quality, and readiness for topline analysis," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "During the quarter, we reached the original 146-patient randomization target, and subsequent progress has moved the trial within six randomizations of expected enrollment closure. This is an important execution phase for IGC-AD1 as we prepare the CALMA dataset for scientific, regulatory, and strategic evaluation following completion of the Phase 2 trial." IGC-AD1 is the Company's lead investigational therapeutic candidate for agitation associated with Alzheimer's dementia, a condition that creates significant burden for patients, caregivers, clinicians, and healthcare systems. CALMA is a randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate IGC-AD1 in this population. Second Quarter and Recent Highlights CALMA Phase 2 progress: CALMA reached the Company's original 146-patient baseline randomization target during the second quarter and is now within 6 additional randomizations of expected enrollment closure. Expected Q4 topline readout: Following enrollment closure, the Company expects to complete patient follow-up, database lock, unblinding, and topline analysis, with Phase 2 topline data anticipated in the fourth quarter of 2026. Management elected equity over cash repayment: On June 30, 2026, IGC Pharma's CEO and Principal Financial Officer agreed to convert approximately $1.15 million of amounts owed by the Company to them, including funds previously loaned to the Company, into 4,274,853 shares of common stock at $0.27 per share, rather than receive cash repayment. The shares issued or issuable in the transaction are expected to be restricted securities subject to applicable holding-period and resale limitations under Rule 144, further aligning management with shareholders as CALMA approaches expected enrollment closure and Q4 2026 topline data. The transaction reduced outstanding obligations, preserved cash, and increased stockholders' equity. Psilocybin authorization: IGC Pharma received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its Bogotá research and development facility. The authorization provides the Company with a regulated capability to evaluate potential applications of psilocybin in neuropsychiatric symptoms associated with dementia, including depression and anxiety. Further regulatory approvals would be required before initiating any clinical trials involving psilocybin. Regulatory and data-readiness activities: IGC Pharma continues strengthening regulatory, biostatistical, AI-enabled data science, and strategic pharmaceutical development capabilities to support clinical data review, data quality activities, regulatory preparedness, and potential strategic evaluation following completion of CALMA. AI-enabled platforms: The Company continued development of AHA, its Agentic Harmonization Assistant for Alzheimer's and aging-related data harmonization, and MINT-AD, its platform for Alzheimer's risk stratification and longitudinal assessment. AHA and MINT-AD are not approved or cleared as diagnostic or therapeutic products. Q2 2026 Financial Summary For the three months ended June 30, 2026, revenue was approximately $265 thousand, compared with approximately $328 thousand for the prior-year quarter. Research and development expenses were approximately $1.4 million, compared with approximately $851 thousand in the prior-year quarter, primarily reflecting continued investment in CALMA and the Company's pharmaceutical development programs. Selling, general and administrative expenses were approximately $1.4 million, compared with approximately $1.2 million in the prior-year quarter. Net loss attributable to common stockholders was approximately $3.0 million, or $0.03 per basic and diluted share, for the three months ended June 30, 2026, compared with approximately $1.6 million, or $0.02 per basic and diluted share, for the prior-year quarter. Cash and cash equivalents were approximately $331 thousand as of June 30, 2026. During the six months ended June 30, 2026, the Company received approximately $1.1 million of net proceeds from equity issuances and approximately $1.3 million of net proceeds from debt financings. Subsequent to quarter-end, the Company raised approximately $687 thousand in gross proceeds under its at-the-market equity program. The Company's liquidity sources include a $12 million revolving working capital credit facility with O-Bank Co., Ltd., with no outstanding amounts as of June 30, 2026. Management believes existing cash, available financing sources, and the Company's ability to access additional debt and equity financing are sufficient to support operations for at least twelve months from the filing date of the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. About IGC Pharma IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company developing novel investigational therapies for Alzheimer's disease, supported by AI-enabled platforms for data harmonization and risk stratification. The Company's lead asset, IGC-AD1, is a cannabinoid-based investigational therapy being evaluated in the Phase 2 CALMA trial for agitation associated with Alzheimer's dementia. The Company's pipeline also includes TGR-63 and earlier-stage neurodegeneration programs. More information is available at . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Phase 2 CALMA trial, anticipated enrollment closure, patient follow-up, database lock, site closeout, unblinding, and the timing and outcome of topline analysis; the clinical and regulatory development strategy for IGC-AD1; the development, capabilities, potential utility, and commercialization of AHA and MINT-AD; the Company's preclinical programs, including TGR-63; the Company's liquidity, capital resources, and financing plans, including equity, debt, non-dilutive funding, and availability under its credit facility; and the future issuance of shares in connection with the management conversion arrangements described above. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to clinical trial timelines and outcomes, patient follow-up, data quality and evaluability, regulatory considerations, software development, validation, third-party and ecosystem adoption, data access and rights, intellectual property protection, commercialization, financing needs, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. The Company undertakes no obligation to update these statements except as required by law. Contact Information Andres Sanchez Investor Relations info@igcpharma.com +1 301-983-0998 / +1 (202) 569-2566 SOURCE: IGC Pharma, Inc. View the original press release on ACCESS Newswire

8月10日至16日，Radix药引共收录 1002条 药物研发动态，本篇精选 21条 自免/代谢/神经领域重点。 本文约980字　阅读约3分钟 信达生物 IBI3027 Ⅲ期 — 治疗中重度特应性皮炎，等效性临床研究。 高德美 Nemolizumab Ⅲ期 — 治疗中国中重度特应性皮炎。 欧加农 本维莫德 Ⅲ期 — 治疗特应性皮炎幼儿，海外拓展至儿童群体。 诗健生物/Escugen ESG206（抗BAFF-R单抗）Ⅱ期 — 治疗系统性红斑狼疮。 argenx Efgartigimod Ⅱ期 — 治疗干燥综合征相关多发性神经病。 威凯尔 VC005 Ⅰ期 — 治疗青少年重度斑秃。同周恒瑞 HRS-7085 / HRS-7590 Ⅰ期均针对溃疡性结肠炎。 葛兰素史克 Efimosfermin alfa Ⅲ期 — 治疗MASH合并肝纤维化。 阿斯利康 AZD5004 Ⅲ期 — 治疗肥胖或超重合并或不合并2型糖尿病。同周勃林格殷格翰 Survodutide Ⅲ期治疗2型糖尿病。 诺和诺德 NNC0487-0111 Ⅰ期 — 治疗肥胖成人能量代谢。同周Alnylam ALN-6222 Ⅰ期（RNAi减重）、勃林格殷格翰 BI 3034701 Ⅰ期同步推进。 信达生物 IBI3040 Ⅰ期 — 用于成人长期体重控制。 Madrigal Resmetirom Ⅱ期 — 治疗儿童及青少年MASH，拓展至低龄人群。 地奥制药 DA-302168S Ⅱ期 — 治疗糖尿病。 齐鲁制药 QLC7401 Ⅰ期 — 用于高胆固醇血症或混合型高脂血症。 豪森药业 HS-10380 Ⅲ期 — 治疗精神分裂症长期安全性研究。 大冢制药 SEP-363856 Ⅲ期 — 治疗广泛性焦虑障碍。Otsuka Centanafadine Ⅲ期 — 治疗成人ADHD伴情绪失调。 Voyager VY1706 Ⅰ期 — 治疗早期阿尔茨海默病。同周Denali DNL921 Ⅰ期、Annovis Buntanetap Ⅲ期、卫材 LEQEMBI Ⅳ期上市后研究。 CRISPR Therapeutics CTX340 Ⅰ/Ⅱ期 — CRISPR基因编辑治疗高血压，首次进入降压领域。 海思科 HSK51155 Ⅰ期 — 安全性、耐受性和药代动力学研究。 上海医药 LT3001 Ⅱ期 — 治疗急性缺血性卒中。 维罗纳大学 沙芬酰胺 Ⅲ期 — 治疗帕金森病伴运动波动患者疼痛。 赛洛西宾，本周三项独立Ⅱ期临床分别由纽约大学（酒精使用障碍）、MD安德森（化疗神经病变预防）、Nicky Mehtani（甲基苯丙胺使用障碍）开展。 Radix药引 — 医药政策智能知识库 本文由 Radix药引 编辑团队整理。